Search

Displaying results 2391 - 2400 of 8517 in total
  1. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. … It has been created to increase the half-life of factor VIII, which decreases dose frequency and decreases the occurrence of bleeding events [A32067], [A32069], [FDA label].

  2. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. … In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation.

  3. Drug

    Rabeprazole

    go.drugbank.com/drugs/DB01129
    ApprovedInvestigational

    Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric...

  4. Drug

    Oxycodone

    go.drugbank.com/drugs/DB00497
    ApprovedIllicitInvestigational

    [A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics … [Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]

  5. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    or as an alternative to erythromycin treatment [A176170]. … This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia [L5737].

  6. Drug

    Gadoteridol

    go.drugbank.com/drugs/DB00597
    ApprovedInvestigational

    [A263076,A263081,L49871] It was 1 of the 3 macrocyclic gadolinium-based contrast agents (GBCAs) that was mandated by the EMA to replace linear gadolinium-based contrast agents due to concerns about retained

  7. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market … Salts of DCA are used as drugs since they inhibit the enzyme pyruvate dehydrogenase kinase.

  8. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets. … Psychomotor symptoms of HD, such as chorea, are related to hyperactive dopaminergic neurotransmission [A14081].

  9. Drug

    Crotamiton

    go.drugbank.com/drugs/DB00265
    Approved

    Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor.

  10. Drug

    Acamprosate

    go.drugbank.com/drugs/DB00659
    ApprovedInvestigational

    It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]